Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several core dosing/administration and safety claims are inconsistent with the provided label excerpts (notably adult starting dose, dosing adjustment rationale, evening dosing, and warfarin/bleeding risk). Many other claims are partially aligned (e.g., dose range, pediatric max dose, monitoring timeframe, common adverse reactions), but multiple unsupported or contradicted statements materially reduce alignment.
Category Scores
Accurate Statements
For adults, the dosage range of Lipitor is 10 to 80 mg once daily.
2.1 Hyperlipidemia: "The dosage range of LIPITOR is 10 to 80 mg once daily."
After initiation or titration, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.
2.1: "After initiation and/or upon titration of LIPITOR, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly."
For children and adolescents (10–17 years), the recommended starting dose is 10 mg/day and the maximum recommended dose is 20 mg/day.
2.2: "The recommended starting dose of LIPITOR is 10 mg/day; the maximum recommended dose is 20 mg/day..."
In children and adolescents, dose adjustments should be made at intervals of 4 weeks or more.
2.2: "Adjustments should be made at intervals of 4 weeks or more."
Commonly reported adverse reactions (≥2% and greater than placebo) include diarrhea and arthralgia.
6.1: "The most commonly reported adverse reactions... were: ... arthralgia (6.9%), diarrhea (6.8%), ..."
Myalgia is among adverse reactions leading to treatment discontinuation in clinical trials.
6.1: "five most common adverse reactions... led to treatment discontinuation... were: myalgia (0.7%), ..."
Unsupported Statements
High LDL cholesterol increases the risk of heart disease and stroke.
The provided excerpts do not state a direct causal relationship between LDL cholesterol level and risk of heart disease and stroke; they describe risk reduction indications.
For children and adolescents, Lipitor is typically prescribed in lower doses of 10–20 mg once daily.
The label excerpt specifies a recommended starting dose (10 mg/day) and maximum dose (20 mg/day) for ages 10–17, but does not support the wording 'typically prescribed' for 10–20 mg.
In children and adolescents, Lipitor dosage may be adjusted based on the child's weight and response to treatment.
No label excerpt supports dose adjustment based on weight for pediatric patients; the label excerpt only states adjustment intervals of 4 weeks or more.
For adults, the typical starting dose of Lipitor is 10–20 mg once daily.
The label excerpt states recommended starting dose is 10 or 20 mg once daily, but does not support the wording 'typical' (as a qualitative descriptor).
For adults, Lipitor dosage may be adjusted up to 80 mg once daily based on the individual's response to treatment and other health factors.
The label excerpt supports titration and the 10–80 mg range, but does not specify adjustment 'based on ... other health factors' in the provided text.
For older adults, Lipitor dosage may need to be adjusted due to potential interactions with other medications and decreased liver function.
The provided label excerpts do not include geriatric-specific dosing adjustment recommendations.
Older adults may require special consideration when taking Lipitor due to potential interactions with other medications and decreased liver function.
No provided label excerpt supports this general older-adult-specific consideration.
When taken with warfarin, Lipitor may increase the risk of bleeding.
No warfarin/bleeding interaction is present in the provided label excerpts.
When taken with warfarin, a doctor may need to adjust the dosage of one or both medications.
No warfarin interaction/dose adjustment statement is present in the provided label excerpts.
Lipitor may increase the levels of digoxin in the blood.
No digoxin interaction is present in the provided label excerpts.
When Lipitor increases digoxin levels, a doctor may need to adjust the dosage of digoxin.
No digoxin interaction/dose adjustment statement is present in the provided label excerpts.
Older adults may have decreased liver function, which can affect the metabolism of Lipitor.
No provided label excerpt supports decreased liver function being specifically common in older adults or affecting metabolism in that manner.
When liver function is decreased, a doctor may need to adjust the Lipitor dosage based on liver function tests.
The label excerpt provides that liver function tests be performed prior to and after initiation and that dose reduction/withdrawal is recommended if ALT/AST persistently elevate >3x ULN; it does not generally state adjustment whenever liver function is decreased.
Lipitor typically starts working within 2–4 weeks of starting treatment.
The label excerpt supports that lipid levels should be analyzed within 2–4 weeks, but does not explicitly state onset of effect within 2–4 weeks.
Common side effects of Lipitor include muscle pain, headache, and digestive issues.
The provided label excerpts include myalgia (muscle pain) and diarrhea/nausea (digestive issues), but do not list headache; therefore the combination and 'common side effects' framing is not fully supported.
If a patient does not see results with Lipitor, a doctor may need to adjust the dosage or switch to a different medication.
The label excerpt supports lipid level testing and dose adjustment within 2–4 weeks after initiation/titration, but does not support switching to a different medication if 'no results' as a stated recommendation.
Contradictions
High
AI Statement
Lipitor is typically taken once daily, in the evening.
Label Reference
2.1: "LIPITOR can be administered as a single dose at any time of the day" (no evening-specific instruction).
Low
AI Statement
For children and adolescents, Lipitor is typically prescribed in lower doses of 10–20 mg once daily.
Label Reference
2.2: "The recommended starting dose ... is 10 mg/day; the maximum recommended dose is 20 mg/day" and "Doses greater than 20 mg have not been studied" (label does not support 'typically prescribed' 10–20 as a conventional range).
Important Omissions
Indication details beyond LDL-lowering (e.g., specific FDA-indicated outcomes such as reduced risk of myocardial infarction, stroke, revascularization/angina, and, for hyperlipidemia, adjunct to diet to reduce specified lipid fractions; plus the listed pediatric indication criteria).
Importance:
Moderate
Label-supported contraindications (active liver disease; pregnancy; nursing mothers) were not mentioned.
Importance:
Moderate
Key label warnings/precautions not covered by the claims provided (e.g., skeletal muscle/myopathy management and liver function monitoring specifics; hemorrhagic stroke risk in patients with recent stroke/TIA).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Contradiction on administration timing (evening-specific instruction) and unsupported warfarin/digoxin interaction/bleeding and dosing adjustment claims could mislead clinical decision-making. Several other statements are unsupported or only partially supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Contains a direct contradiction about administration timing (evening) and includes multiple unsupported drug interaction claims (warfarin/bleeding; digoxin levels) not supported by provided label excerpts.
Suggested Improvement
Replace evening-specific dosing with 'any time of day'; remove or revise unsupported warfarin and digoxin interaction claims; align interaction statements to those supported in the provided label (e.g., strong CYP3A4 inhibitors such as clarithromycin with caution above 20 mg; grapefruit juice; risk with cyclosporine/strong CYP3A4 inhibitors/fibric acid derivatives/niacin). Ensure pediatric dose statements match the label (starting 10 mg/day, max 20 mg/day; adjustments at intervals of ≥4 weeks) and avoid attributing weight-based adjustment without label support.